LM-108 not checked

LaNova Medicines

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
5 active
7 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“LM-108 combined with Toripalimab administered intravenously on Day 1 every 3 weeks”In the company’s words, NCT07362186 on ClinicalTrials.gov
Tested for
Advanced Solid Tumor (3 trials), Locally Advanced or Metastatic GC and GCJ Adenocarcinoma, Advanced Pancreatic Cancer
Main trialPhase 3
“This is a phase III, Multicenter, Randomized study, evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma.”In the company’s words, NCT07362186 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumor

All 2440 drugs for Advanced Solid Tumor

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 17 Aug 2028 LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Phase 2Not yet recruiting 26 Jan 2028 A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Phase 1/2Recruiting Mar 2026 Clinical Studies for the Treatment of Advanced Solid Tumors
Phase 1/2Active, not recruiting 31 Oct 2026 A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
Phase 1/2Recruiting Dec 2027 Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Phase 1/2Terminated 6 Oct 2023 Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
Phase 1/2Completed 31 Dec 2024 Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LM-108

Following is part of Solo: you see every change to LM-108 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in